Enhance.MD Review: What Its GLP-1 Documents Establish—and What They Do Not

Enhance.MD’s most important evidence question is not whether semaglutide and tirzepatide have been studied. It is how much of that research can reasonably describe the particular products and service being sold. The company markets compounded semaglutide, compounded tirzepatide, a combination of the two, and tirzepatide microdosing, alongside NAD+ offerings. Those are distinct propositions. Evidence supporting a studied medicine does not automatically establish the effectiveness of a different formulation, a combination, a microdosing program or the telehealth organization arranging care.

The public documentation consulted October 19, 2026, establishes considerably more about Enhance.MD’s advertised service than about its patients’ measured outcomes. It describes laboratory testing, virtual consultations, medication subscriptions, pharmacy fulfillment and ongoing support. It also contains differences between pages about renewal schedules, participating pharmacies and onboarding steps. This review separates documented offerings from commercial claims and unresolved questions. The aim is to help prospective patients understand what they would be purchasing, what requires confirmation before payment, and where clinical research stops short of validating this provider’s particular programs.

At a glance

Who provides care: Enhance.MD LLC describes itself as an administrative platform, not a medical or pharmacy provider; independent medical groups deliver telehealth care.
Sources: [7] [10]
Documented GLP-1 offerings: Core markets injectable semaglutide, Advanced compounded tirzepatide, and Elite an injectable semaglutide–tirzepatide combination. A separate tirzepatide microdosing program is also advertised.
Sources: [6] [9] [12] [11]
Lowest displayed recurring rates: Core’s $212/mo, Advanced’s $280/mo and Elite’s $322/mo correspond to plans labeled 12 months but billed every 48 weeks, not the four-week billing options.
Sources: [6] [9] [12]
Included service: The main product pages describe four weeks of medication, ongoing provider support, metabolic testing every six months, supplies, wellness coaching and educational access.
Sources: [6] [9] [12]
Approval and evidence boundary: Core explicitly discloses that its compounded formulation is not FDA approved. FDA does not review compounded preparations for safety, effectiveness and quality before marketing.
Sources: [6] [1]

Start with the product, not the ingredient name

Core is marketed as injectable semaglutide for people new to metabolic treatment or seeking moderate weight loss. Advanced markets compounded tirzepatide for stronger appetite control or support after limited results with other GLP-1 medicines. Elite goes further, advertising an injectable combination of semaglutide and tirzepatide for people who have plateaued. These descriptions are Enhance.MD’s positioning, not independently established comparisons showing that its tiers deliver progressively better results. The product pages describe GLP-1 administration as subcutaneous injection.

Core’s disclosure says the compounded formulation requires a prescription and demonstrated clinical need, is not FDA approved, and is compounded under federal Section 503A guidelines. That compliance statement comes from the provider; this review does not independently verify it. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone neither establishes clinical inequivalence nor validates the product. Our guide to approved and compounded medicines explains that distinction.

The separate tirzepatide microdosing offering advertises medication delivery every 12 weeks and ongoing oversight. Its FAQ acknowledges that fewer side effects are not guaranteed and responses vary. NAD+ is another separate offering: the homepage lists subcutaneous injections starting at $169 per month, while product-page blocks also describe sublingual wafers. Their placement among GLP-1 content makes careful product identification important. The consulted documentation does not establish that NAD+ is included in every GLP-1 subscription or that its promotional benefits have been demonstrated for these programs.

Sources: [6] [9] [12] [11] [7] [1]

Clinical trials do not validate the subscription tiers

STEP 1 studied subcutaneous semaglutide in adults with obesity, or overweight plus a weight-related condition, without diabetes, over 68 weeks. Both groups received lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity, or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. These were trials of specific treatments, not evaluations of Enhance.MD. Novo Nordisk funded STEP 1 and Eli Lilly funded SURMOUNT-1; gastrointestinal tolerability was relevant in both.

Neither trial establishes outcomes for Enhance.MD’s compounded formulations, its combined Elite product, its microdosing program or its NAD+ offerings. Nor can separate trial results demonstrate that one of the company’s tiers is superior to another. Our explanation of why trials are not company performance reports addresses this common inference. The consulted documentation does not provide a product-specific evaluation sufficient to adopt clinical-equivalence or bioequivalence claims as verified facts.

A useful evidence request would identify the exact dispensed formulation and ask which research supports that formulation, route and intended use. Ingredient familiarity is not a substitute for that answer. Equally, the absence of provider-specific outcome data is not proof that treatment cannot help anyone. It limits the claims this review can make: the pages document an offering and describe its intended benefits, but they do not establish an Enhance.MD success rate or predict an individual patient’s result.

Sources: [3] [4] [6] [9] [12] [11] [7]

The administrative platform is not the treating practice

Enhance.MD LLC says it supplies administrative and operational support rather than medical or pharmacy services. Its footer identifies Enhance Wellness PC and iThriveMD PC as the practices whose professionals deliver telehealth care. The terms additionally name EnhanceMD CA, PC. This discrepancy does not establish that care is unavailable, but it leaves the public-facing account of clinical responsibility incomplete. Before enrollment, patients can ask which practice will treat them and which entity will hold their clinical relationship.

The company says it does not employ healthcare providers or influence clinical decisions, and payment does not guarantee prescribing or dispensing. Its FAQ describes the clinical team as U.S.-licensed physicians and nurse practitioners; that is a provider statement, not independent credential verification. The terms restrict access to adults 18 or older in states where services are offered. Although the FAQ claims licensing in all 50 states, its product-dependent availability list names only selected states and Washington, D.C.; the broad licensing claim should not be read as universal product availability.

Sources: [7] [10] [8]

Onboarding includes more than an online questionnaire

The initial medical intake asks about lifestyle and medical history and is described as free. The FAQ then places payment before the virtual provider meeting. Identity verification is also necessary: an account can be created without it, but healthcare services cannot proceed. The FAQ requires a full-face photograph and a photograph of government-issued identification. These are meaningful enrollment steps, and the free intake should not be mistaken for an entire free clinical evaluation or a promise of medication.

The detailed process page places Quest Diagnostics testing before consultation, listing a comprehensive metabolic panel, thyroid-stimulating hormone, lipids and hemoglobin A1c as baseline tests. The FAQ estimates that results reach Enhance.MD approximately one to two business days after the laboratory appointment and appear in the dashboard. It then describes an email directing the patient to schedule a video consultation. That laboratory estimate is not a prescription approval, dispatch or delivery promise. Simplified three-step descriptions elsewhere do not fully explain how testing fits every product pathway.

Enhance.MD’s FAQ states minimum BMI thresholds of 25 for new patients and 20 for maintenance patients currently taking or recently having taken GLP-1 treatment, with medical history also affecting the decision. Those are provider-specific screening statements, not general treatment recommendations. NIDDK describes general adult pharmacotherapy thresholds of 30, or 27 with weight-related health problems. The difference deserves discussion with the treating clinician; neither set of numbers independently determines suitability, and this review cannot resolve eligibility for an individual.

Sources: [5] [8] [2]

Read the billing interval beside every advertised price

The homepage’s starting prices emphasize the first month: Core from $112, then $212 per month; Advanced from $180, then $280; and Elite from $222, then $322. On the detailed product pages, those recurring rates belong to plans labeled 12 months and billed every 48 weeks. They are not the rates for the four-week billing option. Four weeks is not a calendar month, and a 48-week billing interval is not a full calendar year. The table preserves the pages’ labels rather than converting them into assumed totals.

For each main program, the 12-, six- and three-month options advertise respective discounts of 15%, 10% and 5%, plus $100 off the first order; the one-month option advertises $50 off the first order. These are provider-advertised discounts, not independently calculated savings. General advertising of up to $150 off is not reconciled by those blocks. The consulted documentation does not clearly establish each longer plan’s total initial collection, partial-refund rules or cancellation penalties. A plan label alone does not establish a minimum commitment or medication quantity.

Microdosing lists $169, $179 and $189 per month for plans labeled 12, six and three months, billed every 48, 24 and 12 weeks. Its one-month block specifies four-week billing without an unambiguous price there. Separately, Enhance.MD promises the same price as a dose increases, but that does not erase price differences among plan lengths. Before paying, obtain the selected product, first charge, subsequent charge and renewal date together in writing rather than relying on a monthly headline.

Main injectable programs: displayed monthly amounts and stated billing intervals
Displayed plan label / billing interval	Core semaglutide / Advanced tirzepatide	Elite semaglutide + tirzepatide
12 months / every 48 weeks	$212/mo / $280/mo	$322/mo
6 months / every 24 weeks	$224/mo / $296/mo	$341/mo
3 months / every 12 weeks	$237/mo / $313/mo	$360/mo
1 month / every 4 weeks	$249/mo / $329/mo	$379/mo

Sources: [6] [9] [12] [7] [11]

Included care is described more clearly than follow-up cadence

The Core, Advanced and Elite pages each describe four weeks of their respective medication, ongoing provider care, metabolic laboratory testing every six months, essential supplies, wellness coaching and educational platform access. Advanced specifically names syringes and alcohol pads. Core advertises free shipping and medication delivery every four weeks. These statements describe the subscription’s advertised scope; they do not establish that a longer billing plan sends its entire period’s medication at once or that any particular transit time is guaranteed.

The private portal lets patients review laboratory results and treatment and communicate with the care team. That is a useful documented access route, but the public materials do not establish a precise follow-up visit schedule, whether each contact is synchronous, or a clinical response-time guarantee. As our guide to clinical follow-up versus renewal explains, payment continuity and care continuity are different questions. NIDDK describes follow-up as involving response and tolerability, not merely continued access to medication.

For administrative questions, the site lists 1-888-299-5088 and support@enhance.md, with hours of 8 a.m.–8 p.m. EDT Monday through Friday and 9 a.m.–5 p.m. EDT on weekends. Those published support hours should not be interpreted as around-the-clock clinical coverage. A useful pre-enrollment question is which channel handles medication concerns outside those hours and who is responsible for a clinical answer. The consulted documentation does not confirm Spanish-language clinical care or support.

Sources: [6] [9] [12] [8] [7] [2]

Pharmacy identity and shipping assurances need product-level answers

The FAQ names Tru Meds Rx, Strive Pharmacy and Pharmacy Hub as fulfillment partners. The terms instead identify Rite-Away Pharmacy, Vios Compounding Pharmacy, TruMedsRx and other licensed pharmacies. These lists overlap only partly, and the consulted documentation does not identify which pharmacy prepares and ships each product in each state. A fulfillment partner’s name alone also does not establish who compounds a preparation. Patients should request the actual dispensing pharmacy and, where applicable, the preparation source for their prescription.

Medication must ship to a physical address. The FAQ allows a prescription to go to a pharmacy chosen by the patient, but says that pharmacy will bill medication costs directly. That exception matters when evaluating the advertised all-in subscription. Neither the laboratory turnaround estimate nor the stated delivery frequency establishes the time from clinical approval to dispatch or arrival. The documentation reviewed does not provide a concrete promise for either stage, and the linked shipping-and-returns policy’s content was not available for this assessment.

General provider assurances about shipping stability do not supply formulation-specific temperature limits or cold-chain documentation. FDA explicitly advises not using an injectable GLP-1 product that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy to resolve the concern. Our guide to reading delivery and cold-chain claims explains why dispatch, arrival and temperature control are separate evidence questions. Free shipping describes a delivery charge, not proof of adequate handling or free treatment.

Sources: [8] [10] [6] [1]

Renewal and refund language leaves important boundaries unresolved

The FAQ describes automatic renewal every 28 days and says pausing or canceling affects prescription refills. Product pages also offer billing every 12, 24 or 48 weeks, without explaining how those schedules fit the general renewal statement. The terms require cancellation before the next billing cycle and defer complete subscription conditions to checkout. Those final checkout terms were not available for this review. Accordingly, the public record does not settle longer-plan cancellation rights, unused-period refunds or the amount that remains payable after cancellation.

The documented money-back protection is narrower than a results guarantee: if onboarding finds the patient ineligible for the formulation, Enhance.MD promises a refund of 100% of the initial payment. The FAQ says refund processing usually takes five to ten business days; that is not a guarantee of bank receipt within that period. Services are cash-pay and not billable to federal or state programs such as Medicare or Medicaid. The FAQ accepts Visa, Mastercard, Discover and American Express, but excludes gift cards, preloaded cards and FSA/HSA cards. Private-insurance reimbursement documentation remains unspecified.

Sources: [8] [10] [6] [9] [12]

Questions & answers

Is Enhance.MD itself the medical practice?

No. Enhance.MD LLC describes itself as an administrative platform. Named medical groups provide telehealth care, and the terms list one more group than the footer does. Ask which practice and clinician will be responsible for your care. The platform also states that paying does not guarantee a prescription or dispensing.

Sources: [7] [10]

Can I enroll in Core for $112 and then pay $212 every four weeks?

That is not what the product page establishes. The homepage advertises Core starting at $112 for the first month and $212 per month afterward, but the detailed $212 rate belongs to the plan labeled 12 months, billed every 48 weeks. The one-month option displays $249/mo with four-week billing and $50 off the first order.

Sources: [7] [6]

Are laboratory tests actually part of onboarding?

The detailed process and FAQ describe testing before the video consultation. The process page names Quest Diagnostics and baseline metabolic, thyroid, lipid and A1c testing. Results are estimated to reach the company one to two business days after the laboratory appointment. Because simplified descriptions omit steps, confirm the sequence for your selected program before payment.

Sources: [5] [8]

Does Elite have demonstrated advantages over Core or Advanced?

The consulted documentation does not establish that comparison. Elite markets a semaglutide–tirzepatide combination for people seeking stronger control or who have plateaued. STEP 1 and SURMOUNT-1 did not test Enhance.MD’s combination or compare its subscription tiers. The commercial positioning therefore should not be treated as a demonstrated ranking of clinical outcomes.

Sources: [12] [3] [4]

Can Enhance.MD send a prescription to my preferred pharmacy?

The FAQ says yes, but medication costs are billed directly to you when using that option. Do not assume the advertised subscription price covers an outside pharmacy’s charge. Also ask what platform or care charges remain. For partner fulfillment, the FAQ and terms name different pharmacy networks, so request the actual pharmacy assigned to your prescription.

Sources: [8] [10]

Does canceling guarantee a refund?

No general cancellation refund is established in the consulted documentation. The explicit guarantee covers the initial payment when onboarding determines that the patient is ineligible. Cancellation must occur before the next billing cycle to avoid renewal, but longer-plan refund boundaries remain unclear. The stated five-to-ten-business-day refund processing period does not guarantee when funds reach a bank account.

Sources: [6] [10] [8]

Our assessment

Enhance.MD documents a substantive telehealth package: baseline testing, a clinician consultation, prescription-dependent medication access, supplies, periodic laboratory work and ongoing communication. Its explicit compounded-product disclosure and onboarding-ineligibility refund are useful details. However, its marketing reaches further than the product-specific evidence available in the consulted documentation, particularly for Elite and microdosing. The most consequential practical gaps concern longer-plan charges and refunds, conflicting renewal descriptions, the assigned pharmacy and the precise follow-up arrangement. Before paying, obtain a written summary naming the medical practice, formulation, dispensing pharmacy, first and subsequent charges, renewal date and cancellation terms. Those answers can clarify the purchase; they cannot substitute for a clinician’s assessment or transform ingredient-level research into demonstrated outcomes for Enhance.MD.

Visit Enhance.MD’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Enhance.MD Review: What Its GLP-1 Documents Establish—and What They Do Not

At a glance

01Start with the product, not the ingredient name

02Clinical trials do not validate the subscription tiers

03The administrative platform is not the treating practice

04Onboarding includes more than an online questionnaire

05Read the billing interval beside every advertised price

06Included care is described more clearly than follow-up cadence

07Pharmacy identity and shipping assurances need product-level answers

08Renewal and refund language leaves important boundaries unresolved